Inactive Instrument

News Concert Pharmaceuticals, Inc.

Equities

CNCE

US2060221056

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Alopecia Areata Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)	23-09-27	AQ
SUN PHARMA - LATE-BREAKING PHASE 3 DATA AT AAD 2023 SHOW ORAL INVESTIGATIONAL MEDICINE DEURUXOLITINIB SIGNIFICANTLY IMPROVED SCALP HAIR REGROWTH IN ALOPECIA AREATA	23-03-20	AQ
Concert Pharmaceuticals Announces the Presentation of Data from its Phase 3 Clinical Trial, THRIVE-AA2	23-03-18	CI
Sun Pharmaceutical Completes Acquisition of Concert Pharmaceuticals	23-03-06	MT
CONCERT PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	23-03-06	AQ
Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from NASDAQ Composite Index	23-03-06	CI
Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from S&P Global BMI Index	23-03-06	CI
Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from S&P TMI Index	23-03-06	CI
Sun Pharmaceutical Industries Limited completed the acquisition of Concert Pharmaceuticals, Inc..	23-03-05	CI
Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from NASDAQ Biotechnology Index	23-03-03	CI
North American Morning Briefing : Rising Yields -3-	23-03-02	DJ
Concert Pharmaceuticals Says Deuruxolitinib Maintains FDA Breakthrough Therapy Designation to Treat Alopecia Areata	23-02-15	MT
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata	23-02-15	BU
Concert Pharmaceuticals, Inc. Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata	23-02-15	CI
Insider Sell: Concert Pharmaceuticals	23-01-31	MT
North American Morning Briefing : Stock Futures -3-	23-01-23	DJ
CONCERT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Concert Pharmaceuticals, Inc. - CNCE	23-01-20	BU
JMP Securities Downgrades Concert Pharmaceuticals to Market Perform From Market Outperform	23-01-20	MT
Truist Downgrades Concert Pharmaceuticals to Hold Rating From Buy, Adjusts Price Target to $9 From $25	23-01-20	MT
Jefferies Downgrades Concert Pharmaceuticals to Hold From Buy, Adjusts Price Target to $9 From $15	23-01-20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Concert Pharmaceuticals, Inc.

Equities

CNCE

US2060221056

Summary

Filters